Iveta Kolářová

Sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer: a secondary analysis of the CEBCC-102 real-world cohort

Abstract Background Real-world evidence on sacituzumab govitecan (SG) in heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC) remains limited. This study assessed SG outcomes in a multicentre Central European cohort. Methods This retrospective study i...